Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Locally Advanced or Metastatic Breast Cancer
Interventions: DRUG: utidelone|DRUG: docetaxel
Sponsor: Sun Yat-sen University
Collaborators: Beijing Biostar Pharmaceuticals Co., Ltd.|Hunan Cancer Hospital